Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Ublituximab, umbralisib and ibrutinib in CLL and NHL

Loretta Nastoupil • 2 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies Ibrutinib Ublituximab Umbralisib

The combination of ublituximab, umbralisib and ibrutinib was investigated in an open-label, Phase I dose escalation and expansion trial in chronic lymphocytic leukemia or R/R B-cell non-Hodgkin lymphoma (NCT02006485). We spoke to Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, about the results seen with this chemo-free triplet regimen. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Loretta Nastoupil

1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals